Lilly’s GLP-1 Oral Medication Orforglipron Shows 27.3lbs Weight Loss in Adults with Obesity
Lilly, a leading medicine company, has announced that its oral GLP-1 medication orforglipron delivered significant weight loss results in adults with obesity, achieving an average of up to 27.3 pounds in the first two pivotal Phase 3 trials. The ATTAIN-1 trial demonstrated orforglipron’s efficacy and safety profile, showing superior body weight reduction compared to placebo … Read more